Poxvirus Vaccine for Advanced Pancreatic Cancer
Author Information
Author(s): Howard L Kaufman, Seunghee Kim-Schulze, Kelledy Manson, Gail DeRaffele, Josephine Mitcham, Kang Seok Seo, Dae Won Kim, John Marshall
Primary Institution: Columbia University
Hypothesis
Can a poxvirus-based vaccine improve immune response and survival in patients with advanced pancreatic cancer?
Conclusion
Poxvirus vaccination is safe, well tolerated, and capable of generating antigen-specific immune responses in patients with advanced pancreatic cancer.
Supporting Evidence
- All patients developed antibody responses against vaccinia virus.
- 62.5% of evaluable patients showed antigen-specific T cell responses.
- Median overall survival was significantly longer in patients with immune responses.
Takeaway
This study tested a new vaccine for pancreatic cancer and found it to be safe and able to help the immune system fight the cancer.
Methodology
Ten patients received a prime-boost vaccination regimen with poxviruses expressing tumor antigens and costimulatory molecules, followed by immune analysis.
Potential Biases
Potential bias due to the small number of patients and lack of a control group.
Limitations
The study had a small sample size and was not designed to detect clinical responses.
Participant Demographics
Patients were predominantly Caucasian, with a mean age of 57.9 years, and most had metastatic disease.
Statistical Information
P-Value
0.002
Statistical Significance
p = .002
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website